ArticleRSC advances2025
High-efficiency encapsulation and pH-triggered release of docetaxel from folic acid-functionalized ZIF-90 nanocarriers.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Puerarin‑Loaded pH‑Responsive ZIF‑90 Nanoparticles Ameliorate Osteoporosis via Enhancing H3K18 Lactylation and Suppressing Aberrant Osteoclast Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Sustained release of Eugenol from MCM-41 mesoporous silica for preservation ofFood chemistry: X · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-organic frameworks (MOFs) offer promising features for drug delivery owing to their high porosity, tunable structures, and surface functionality. Among them, zeolitic imidazolate framework-90 (ZIF-90) is notable for its aldehyde groups, which enable facile functionalization and enhanced biocompatibility. In this work, we report folic acid-modified ZIF-90 nanoparticles as pH-responsive carriers for docetaxel (DTX), a widely used chemotherapeutic agent for breast cancer. The nanocarriers displayed a uniform nanoscale morphology and achieved a high encapsulation efficiency of 92.8% with a drug loading capacity of 8.43%.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.